nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

06.01.2021 | Retinal Disorders

Difference in treatment burden of neovascular age-related macular degeneration among different types of neovascularization

verfasst von: Ji Hyun Lee, Jae Hui Kim, Jong Woo Kim, Chul Gu Kim, Dong Won Lee

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the difference in the treatment burden among different types of neovascular age-related macular degeneration (AMD).

Methods

This retrospective, observational study included 431 patients who were diagnosed with neovascular AMD. Patients were divided into three groups: type 1 or 2 neovascularization group (n = 167), type 3 neovascularization group (n = 50), and polypoidal choroidal vasculopathy (PCV) group (n = 214). The number of hospital visits per year and the number of anti-vascular endothelial growth factor (VEGF) injections per year were compared among these groups. Furthermore, the incidence of bilateral involvement during the follow-up period was compared among the groups.

Results

The mean follow-up period was 50.6 ± 11.3 months. The number of hospital visits per year was significantly higher in the type 1 or 2 neovascularization group (mean: 6.1 ± 1.5) and type 3 neovascularization (6.6 ± 1.6) than in the PCV group (6.0 ± 1.5) (P < 0.001). The number of anti-VEGF injections per year was significantly higher in type 3 neovascularization group (3.1 ± 1.7) than in the type 1 or 2 neovascularization group (2.3 ± 1.5) or the PCV group (2.3 ± 1.2) (P = 0.042). There was a significant difference in the incidence of bilateral involvement among patients in type 1 or 2 neovascularization group (20.4%), type 3 neovascularization group (46.0%), and the PCV group (15.4%) (P < 0.001).

Conclusions

The high frequency of hospital visits and that of anti-VEGF injections in patients with type 3 neovascularization suggests high treatment burden in these patients. The high incidence of bilateral involvement could be one of the primary reasons for high treatment burden in patients with type 3 neovascularization.

Bressler SB, Bressler NM, Fine SL, Hillis A, Murphy RP, Olk RJ, Patz A (1982) Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol 93:157–163PubMedCrossRef

Guyer DR, Fine SL, Maguire MG, Hawkins BS, Owens SL, Murphy RP (1986) Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol 104:702–705PubMedCrossRef

Sloan FA, Hanrahan BW (2014) The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration. JAMA Ophthalmol 132:456–463PubMedPubMedCentralCrossRef

Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, Cougnard-Gregoire A, Merle BMJ, Korb C, Erke MG, Bron A, Anastasopoulos E, Meester-Smoor MA, Segato T, Piermarocchi S, de Jong P, Vingerling JR, Topouzis F, Creuzot-Garcher C, Bertelsen G, Pfeiffer N, Fletcher AE, Foster PJ, Silva R, Korobelnik JF, Delcourt C, Klaver CCW (2017) Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology 124:1753–1763PubMedCrossRef

Korobelnik JF, Moore N, Blin P, Dharmani C, Berdeaux G (2006) Estimating the yearly number of eyes with treatable neovascular age-related macular degeneration using a direct standardization method and a markov model. Invest Ophthalmol Vis Sci 47:4270–4276PubMedCrossRef

Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106–e116PubMedCrossRef

Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, Matsumoto Y, Sorenson JA, Yannuzzi L (2008) Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 28:201–211PubMedCrossRef

Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416–434PubMedCrossRef

Cohen SY, Creuzot-Garcher C, Darmon J, Desmettre T, Korobelnik JF, Levrat F, Quentel G, Palies S, Sanchez A, de Gendre AS, Schluep H, Weber M, Delcourt C (2007) Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol 91:1173–1176PubMedPubMedCentralCrossRef

10.

Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Age-related differences in the prevalence of subtypes of neovascular age-related macular degeneration in the first diagnosed eye. Graefes Arch Clin Exp Ophthalmol 257:891–898PubMedCrossRef

11.

Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22PubMedCrossRef

12.

Engelbert M, Zweifel SA, Freund KB (2009) “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 29:1424–1431PubMedCrossRef

13.

Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Cho SY (2018) Difference in treatment outcomes according to optical coherence tomography-based stages in type 3 neovascularization (retinal angiomatous proliferation). Retina 38:2356–2362PubMedCrossRef

14.

Yannuzzi LA, Sorenson J, Spaide RF, Lipson B (1990) Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 10:1–8PubMedCrossRef

15.

Balaratnasingam C, Lee WK, Koizumi H, Dansingani K, Inoue M, Freund KB (2016) Polypoidal choroidal vasculopathy: a distinct disease or manifestation of many? Retina 36:1–8PubMedCrossRef

16.

Li M, Dolz-Marco R, Messinger JD, Sloan KR, Ferrara D, Curcio CA, Freund KB (2019) Clinicopathologic correlation of aneurysmal type 1 neovascularization in age-related macular degeneration. Ophthalmol Retina 3:99–111PubMedCrossRef

17.

Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, Gomi F, Koh AH, Lee WK, Wong TY (2018) Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology 125:708–724PubMedCrossRef

18.

Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB (2010) Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 149(939–946):e931

19.

Chang YS, Kim JH, Yoo SJ, Lew YJ, Kim J (2016) Fellow-eye neovascularization in unilateral retinal angiomatous proliferation in a Korean population. Acta Ophthalmol 94:e49–e53PubMedCrossRef

20.

Kim JH, Kim JW, Kim CG, Lee DW (2019) Visual prognosis in the better-seeing eyes of patients with unilateral polypoidal choroidal vasculopathy. Optom Vis Sci 96:686–694PubMedCrossRef

21.

Gross NE, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA (2005) Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 25:713–718PubMedCrossRef

22.

Nagiel A, Sarraf D, Sadda SR, Spaide RF, Jung JJ, Bhavsar KV, Ameri H, Querques G, Freund KB (2015) Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography. Retina 35:638–647PubMedCrossRef

23.

Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100–110PubMedCrossRef

24.

Kim JH, Kim JW, Kim CG, Lee DW (2019) Focal retinal pigment epithelium atrophy at the location of type 3 neovascularization lesion: a morphologic feature associated with low reactivation rate and favorable prognosis. Graefes Arch Clin Exp Ophthalmol 257:1661–1669PubMedCrossRef

25.

Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583PubMedCrossRef

26.

Spaide R (2007) Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 143:679–680PubMedCrossRef

27.

Prenner JL, Halperin LS, Rycroft C, Hogue S, Williams Liu Z, Seibert R (2015) Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol 160(725–731):e721

28.

Gohil R, Crosby-Nwaobi R, Forbes A, Burton B, Hykin P, Sivaprasad S (2015) Caregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degeneration. PLoS One 10:e0129361PubMedPubMedCentralCrossRef

29.

Mueller S, Agostini H, Ehlken C, Bauer-Steinhusen U, Hasanbasic Z, Wilke T (2016) Patient preferences in the treatment of neovascular age-related macular degeneration: a discrete choice experiment. Ophthalmology 123:876–883PubMedCrossRef

30.

Steinbrook R (2006) The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 355:1409–1412PubMedCrossRef

31.

Cohen SY, Bremond-Gignac D, Quentel G, Mimoun G, Citterio T, Bisot-Locard S, Beresniak A (2008) Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 246:1527–1534PubMedCrossRef

32.

Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS (2019) Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States. JAMA Ophthalmol 138:40–47PubMedCentralCrossRef

33.

Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR (2015) Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122:2514–2522PubMedCrossRef

34.

Maguire MG, Daniel E, Shah AR, Grunwald JE, Hagstrom SA, Avery RL, Huang J, Martin RW, Roth DB, Castellarin AA, Bakri SJ, Fine SL, Martin DF (2013) Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120:2035–2041PubMedCrossRef

35.

Chaudhary V, Gusenbauer K, Mak M, Barbosa J, Mohammad Mohaghegh PS, Popovic M (2016) Waiting room educational media effect on preinjection anxiety for initial intravitreal injections. Can J Ophthalmol 51:71–75PubMedCrossRef

36.

Doguizi S, Sekeroglu MA, Inanc M, Anayol MA, Yilmazbas P (2018) Evaluation of pain during intravitreal aflibercept injections. Eur J Ophthalmol 28:63–67PubMedCrossRef

37.

Nguyen NCI, Fabro F, Ambresin A, Ezziat S, Bergin C, Mazzocato C, Mantel I (2018) Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor. Eye (Lond) 32:1544–1546CrossRef

38.

Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S, Bogumil T, Heah T, Sivaprasad S (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99:220–226PubMedCrossRef

39.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Kitamei H, Shioya S (2013) Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol 97:617–621PubMedCrossRef

40.

Tsai ASH, Cheung N, Gan ATL, Jaffe GJ, Sivaprasad S, Wong TY, Cheung CMG (2017) Retinal angiomatous proliferation. Surv Ophthalmol 62:462–492PubMedCrossRef

41.

Hong T, Mitchell P, Burlutsky G, Samarawickrama C, Wang JJ (2014) Visual impairment and the incidence of falls and fractures among older people: longitudinal findings from the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 55:7589–7593PubMedCrossRef

42.

Koh GC, Tai BC, Ang LW, Heng D, Yuan JM, Koh WP (2013) All-cause and cause-specific mortality after hip fracture among Chinese women and men: the Singapore Chinese Health Study. Osteoporos Int 24:1981–1989PubMedCrossRef

43.

Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK (2009) Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 116:1740–1747PubMedCrossRef

44.

Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623–1628PubMedCrossRef

45.

Kim JH, Chang YS, Kim JW, Kim CG, Lee DW, Kim HS (2019) Long-term visual changes in initially stronger fellow eyes in patients with unilateral type 3 neovascularization. Retina 39:1672–1681PubMedCrossRef

46.

Elshout M, van der Reis MI, de Jong-Hesse Y, Webers CA, Schouten JS (2016) Distinguishing between better and worse visual acuity by studying the correlation with quality of life in neovascular age-related macular degeneration. Ophthalmology 123:2408–2412PubMedCrossRef

47.

Brown MM, Brown GC, Lieske HB, Tran I, Turpcu A, Colman S (2016) Societal costs associated with neovascular age-related macular degeneration in the United States. Retina 36:285–298PubMedCrossRef

48.

Kim JH, Chang YS, Kim JW, Kim CG, Lee DW (2019) Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment. Graefes Arch Clin Exp Ophthalmol 257:1183–1189PubMedCrossRef

49.

Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303–2310PubMedCrossRef

50.

Hatz K, Prunte C (2016) Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 100:1341–1345PubMedCrossRef

51.

Kim JH (2020) Results of switching from pro re nata to treat-and-extend regimen in treatment of patients with type 3 neovascularization. Semin Ophthalmol 35:33–40PubMedCrossRef

52.

Baek J, Lee JH, Kim JY, Kim NH, Lee WK (2016) Geographic atrophy and activity of neovascularization in retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 57:1500–1505PubMedCrossRef

53.

Matsumoto H, Sato T, Morimoto M, Mukai R, Takahashi M, Hiroe T, Ehara K, Takayama M, Mimura K, Kishi S (2016) Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation. Retina 36:2282–2289PubMedCrossRef

54.

Arias L, Cervera E, Vilimelis JC, Escobar JJ, Escobar AG, Zapata M (2020) Efficacy and safety of a treat-and-extend regimen with aflibercept in treatment-naive patients with type 3 neovascularization: a 52-week, single-arm, multicenter trial. Retina 40:1234–1244PubMedCrossRef

55.

Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR : a randomized controlled trial. Adv Ther 37:1173–1187PubMedPubMedCentralCrossRef

56.

Baek SK, Kim JH, Kim JW, Kim CG (2019) Increase in the population of patients with neovascular age-related macular degeneration who underwent long-term active treatment. Sci Rep 9:13264PubMedPubMedCentralCrossRef

57.

Talks J, Daien V, Finger RP, Eldem B, Sakamoto T, Cardillo JA, Mitchell P, Wong TY, Korobelnik JF (2019) The use of real-world evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Surv Ophthalmol 64:707–719PubMedCrossRef

Titel: Difference in treatment burden of neovascular age-related macular degeneration among different types of neovascularization
verfasst von: Ji Hyun Lee
Jae Hui Kim
Jong Woo Kim
Chul Gu Kim
Dong Won Lee
Publikationsdatum: 06.01.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 7/2021
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-020-05028-5

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Choroidal thickness profile and clinical outcomes in eyes with polypoidal choroidal vasculopathy

Clinico-demographic profile and outcomes of 25-gauge vitrectomy in advanced stage 5 retinopathy of prematurity

Macular microhole and foveal red spot syndrome: a critical review of the literature

May ganglion cell complex analysis be a marker for glaucoma susceptibility in unilateral Fuchs’ uveitis syndrome?

Corneal reconstruction in chemically damaged cornea using temperature responsive surface assisted mesenchymal stem cell transplantation in rabbits

Quantitative assessment of choriocapillaris flow deficits in eyes with macular neovascularization

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde